For many advanced practitioners, patients with hematologic malignancies may present infrequently due to the rarity of occurrence. The heterogenous presentation and clinical course of these diseases, along with the fast pace of scientific discovery, creates a challenging environment for clinicians to stay up to date on clinical management. This collection of presentations provides advanced practitioners with a comprehensive overview of treatment strategies and best practices for the side-effect management of novel therapies for various hematologic malignancies.

Clinical Management of Novel Therapies for Hematologic Malignancies: Targeted Therapies, CAR-T, and Beyond

This activity is supported by educational grants provided by Amgen, AstraZeneca, Celgene Corporation, Incyte Corporation, Merck Sharp & Dohme Corp., Takeda Oncology, Pharmacyclics LLC, an AbbVie Company, and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC.

Program Chair

Sandra E. Kurtin, PhDc, ANP-C, AOCN®
Arizona Cancer Center

Faculty

Amy Goodrich, MSN, CRNP
Johns Hopkins School of Medicine, Kimmel Cancer Center

Faculty

Patrick J. Kiel, PharmD, BCPS, BCOP
IU Simon Cancer Center

Faculty

Jean A. Ridgeway, DNP, APN, NP-C, AOCN®
The University of Chicago Medicine

Faculty

Barbara Rogers, CRNP, MN, AOCN®, ANP-BC
Fox Chase Cancer Center

 

Risk-Adapted Treatment of Aggressive B-Cell Lymphomas: Application of Novel Agents

Barbara Rogers, CRNP, MN, AOCN®, ANP-BC
Fox Chase Cancer Center

Posted: 7/16/2018
Expires: 7/16/2019

Credits/Contact Hours: 1.5

Access the Activity for Credit*
   
Participate Without Claiming Credit

* This link will take you to the Annenberg Center for Health Sciences website.

 

Risk-Adapted Treatment of Indolent B-Cell Lymphomas: Application of Novel Agents

Amy Goodrich, MSN, CRNP
Johns Hopkins Kimmel Cancer Center

Posted: 7/16/2018
Expires: 7/16/2019

Credits/Contact Hours: 1.0

Access the Activity for Credit*
   
Participate Without Claiming Credit

* This link will take you to the Annenberg Center for Health Sciences website.

 

Emerging Therapies for Multiple Myeloma

Patrick J. Kiel, PharmD, BCPS, BCOP
IU Simon Cancer Center

Posted: 7/16/2018
Expires: 7/16/2019

Credits/Contact Hours: 0.75

Access the Activity for Credit*
   
Participate Without Claiming Credit

* This link will take you to the Annenberg Center for Health Sciences website.

 

Emerging Therapies for Hodgkin Lymphoma

Patrick J. Kiel, PharmD, BCPS, BCOP
IU Simon Cancer Center

Posted: 7/16/2018
Expires: 7/16/2019

Credits/Contact Hours: 0.50

Access the Activity for Credit*
   
Participate Without Claiming Credit

* This link will take you to the Annenberg Center for Health Sciences website.

 

Risk-Adapted Treatment of Ph- Myeloproliferative Neoplasms

Sandra E. Kurtin, PhDc, ANP-C, AOCN®
Arizona Cancer Center

Posted: 7/16/2018
Expires: 7/16/2019

Credits/Contact Hours: 1.0

Access the Activity for Credit*
   
Participate Without Claiming Credit

* This link will take you to the Annenberg Center for Health Sciences website.

 

Risk-Adapted Treatment of Acute Myelogenous Leukemia

Jean A. Ridgeway, DNP, APN, NP-C, AOCN®
The University of Chicago Medicine

Posted: 7/16/2018
Expires: 7/16/2019

Credits/Contact Hours: 1.25

Access the Activity for Credit*
   
Participate Without Claiming Credit

* This link will take you to the Annenberg Center for Health Sciences website.

These CME/CE/CPE certified activities are jointly provided by

JADPRO CE Logo Harborside Press Logo APSHO Logo Annenberg Logo
Copyright © 2010-2018 Harborside Press, LLC All rights reserved.               
Home | Current Issue | Previous Issue | Submissions | About JADPRO | Advertising | Privacy Policy | Contact | Copyright Notice/Disclaimer | Subscribe
Bot trap - Don't go here
By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.